Advances in modern science have brought about rapid developments in medicinal treatment. As a result, the mortality rate has declined in industrialized countries, and the types of prevalent disease have changed dramatically. Namely, the number of patients suffering from particular chronic diseases has been increasing. However, most of the modern medicines are allopatic and cannot cure chronic diseases such as hypertension, diabetes, or allergic diseases. Due to the ineffectiveness of modern medicine against chronic diseases as well as the possibility of side effects, many patients choose to explore complementary/alternative medicines, and medicinal botanicals in particular.
However, the main stream of medical treatment for chronic diseases is based on modern medicine in general. Since kampo medicine and modern medicine have their own characteristics mentioned above, it is ideal that these medicines should be combined, making up for defects of each other and expecting their synergistic action. Although toxicity and therapeutic failure have long been recognized as possible consequences of the interactions among modern medicines, little is known about the incidence and consequences of interactions between modern and kampo medicines. Studies on their interactions are extensively conducted, and predictable adverse effects must be avoided. 4) Based on our analysis for the prescription issued by Japanese physicians to treat allergic rhinitis, Sho-seiryu-to (SST;
, xiao-longqing-tang in Chinese, minor blue dragon in English) and azelastine hydrochloride are found as the most frequent combination between kampo and modern medicines. SST is the most usable kampo herbal formula to treat allergic symptoms such as rhinitis, asthma, and pollinosis, 5, 6) and azelastine is one of anti-histamines frequently used to suppress allergic symptoms in clinic. 7) Previous studies revealed that SST delays the oral absorption of carbamazepine in rats, 8) and that SST strongly inhibits the activity of cytochrome P450 (CYP) 3A obtained from male rats in vitro.
9) Therefore, it might be possible that SST and azelastine would interact to exhibit disadvantage or adverse effects in clinic. In this study, we evaluated whether SST might disturb the pharmacokinetics of azelastine, which would be important drug information to conduct combined therapy with modern and kampo medicines.
MATERIALS AND METHODS
Materials Sho-seiryu-to (SST) in the form of spraydried powder extract (Lot No. RSEIE) was supplied by Kanebo Ltd. (Tokyo, Japan). The human daily dose of SST (5.2 g) contained the extract of the following herbs: Ephedrae Herba (3.0 g), Paeoniae Radix (3.0 g), Glycyrrhizae Radix (3.0 g), Cinnamomi Cortex (3.0 g), Asiasari Radix (3.0 g), Schisandrae Fructus (3.0 g), Pinelliae Tuber (6.0 g) (Pharmacopoeia of Japan XIV, 10) respectively), and Zingiber Siccatum Rhizoma (3.0 g). These medicinal herbs were boiled in 20-times their weight of H 2 O for 60 min, then the decoction was spray-dried in a hot air stream. Three-dimensional HPLC chromatogram of SST is shown in Fig. 1 . The extract contained 0.37 (w/w)% of ephedrine measured according to Japanese Pharmacopoeia IVX. 10) Azelastine hydrochloride was supplied by Eisai Co. Ltd. (Tokyo). Imipramine hydrochloride, ephedrine hydrochloride, and ketamine hy-Sho-seiryu-to (SST) is widely used herbal formula in Japanese traditional medicine (kampo) to treat allergic diseases. Since Japanese physicians frequently prescribe this formula combined with azelastine hydrochloride, one of anti-histamine and anti-allergic medicines, we evaluated the pharmacokinetic interactions between SST and azelastine hydrochloride in rats to obtain the drug information for the prevention from disadvantage or adverse effects by their combined therapy. Oral administration of SST did not influence the plasma concentration profile of azelastine after its intravaneous injection, suggesting that SST would not change the activities of metabolic enzymes such as cytochrome P450s. However, maximum concentration (C max ) of azelastine after oral administration of azelastine hydrochloride was significantly reduced and mean residence time (MRT) was significantly lengthened when SST was orally administered at 20 times amount of human daily dosage. There was not significant difference in the area under the plasma concentration-time curve (AUC), suggesting that SST might delay the absorption of azelastine without affecting the extent of bioavailability. Since this delay was independent of ephedrine that is a main constituent of SST and that a suppressor for gastric transit, SST might form unsoluble complex with azelastine to reduce its absorption. At the double of human daily dose, SST did not made the absorption of azelastine delay. The possibility that SST reduce the absorption of azelastine hydrochloride could not be denied completely, however, it is suggested that SST would not cause pharmacokinetic interaction with azelastine hydrochloride clinically. Pharmacokinetic Experiments Eight week-old female SD rats were housed in a temperature-controlled room (23Ϯ1°C) under a 12-h light-dark cycle. This female strain was selected because they have more similar metabolic enzymes to human than other strains.
11) Each rat was anesthetized with intraperitoneal injection of ketamine (100 mg/kg), and the jugular vein was cannulated with PE-50 tubing (Becton Dickinson Co., Sparks, MD, U.S.A.) to collect blood samples with an established heparin-lock using 100 U/ml heparin in saline. Azelastine hydrochloride was administered orally or intravenously, and blood samples (0.2 ml) were sequentially collected via the cannula. SST, ephedrine hydrochloride or the vehicle was orally administered 4 times at 37, 25, 13 and 1 h before azelastine-treatment.
Analysis for Plasma Concentration of Azelastine The plasma azelastine concentrations samples were analyzed using a high-performance liquid chromatography-mass spectrometry (HPLC-MS) system (QP-8000a, Shimadzu, Kyoto, Japan). Internal standard (imipramine hydrochloride, 0.5 mg/ml in 5 N HCl, 20 ml) and acetone (400 ml) were added to the plasma sample (50 ml) and mixed vigorously. For the standard sample, azelastine hydrochrolide was dissolved into plasma from normal rats at a concentration from 2 to 500 (azelastine) ng/ml. After centrifugation (14000 rpm, 5 min), the supernatant was transferred to another tube and dried up at room temperature. The residue was reconstituted with 80 ml of mobile phase mentioned below, and 50 ml was injected into the HPLC-MS system. The HPLC conditions were as follows: column, YMC J'sphare H80 4.6ϫ15 mm; mobile phase, MeCN/H 2 O/AcOH 24 : 76 : 0.1; flow rate, 1.0 ml/min; column temperature, 40°C; detection, mass spectrometer using APCI(ϩ) probe. Linear regression was ] 281.4, t R 8.6 min). The within-day and betweenday coefficients of variation were less than 2.0% and 5.0%, respectively. The recovery rate of azelastine in plasma was 97%. The calibration line, which had r 2 value over 0.998, was accepted to determine the plasma azelastine concentration. The concentrations of all samples were within the detectable range (2.00-500 ng/ml).
Pharmacokinetic Analysis The plasma concentrationtime data of intravenously administered azelastine hydrochloride were assessed by two-compartmental analysis using MULTI, 12) a curve-fitting computer program based on nonlinear least squares method, and pharmacokinetic parameters including predicted concentration at time zero (C 0 ), the area under the plasma concentration-time curve (AUC), volume of distribution (V d ), rate of elimination (k e ), half life of distribution phase (t 1/2dist ) and half life of elimination phase (t 1/2elim ). The plasma concentration-time data of orally administered azelastine hydrochloride of each rat was assessed by non-compartment analysis using MOMENT (Excel   ®   ) 13) based on the moment analytic method, 14) and pharmacokinetic parameters including AUC, mean residence time (MRT), variance of residence time (VRT), half life (t 1/2 ), total clearance (CL), and steady-state volume of distribution (V dss ) were obtained. The peak plasma concentration (C max ) and the time to reach C max (T max ) of orally administered azelastine hydrochloride were obtained from the actual data observed after oral administration.
Statistical Analysis Data are expressed as meanϮS.E. Analyses were performed using Student's t-test and repeated measures one-way analysis of variance (ANOVA) by computer software Statview ® . A difference of pϽ0.05 was considered statistically significant.
RESULT AND DISCUSSION
The previous in vitro studies revealed that SST strongly inhibited CYP3A obtained from rat. 9) Since the metabolism of azelastine in human liver is related to CYP3A4, 15) it is sus- pected that SST inhibts the metabolism of azelastine in vivo. Therefore, we at first conducted the experiment to evaluate whether SST would effect on the pharmacokinetics of azelastine administered by intravenous injection. Figure 2 shows the profiles of plasma azelastine concentration after the intravenous injection into the rats pretreated with and without SST (1 g/kg, twice a day, p.o.). Pharmacokinetic parameters were assessed by a two-compartment model, and shown in Table 1 . This dosage of SST was much higher than human daily dose (about 20-times amount), however, there are no statistical significance in the pharmacokinetic parameters between control and SST-treated rats. This result suggests that orally administered SST would not inhibit metabolizing enzymes and the elimination of azelastine in vivo.
Since azelastine hydrochloride is usually taken by oral route to the patients, it was therefore appropriate to evaluate the interactions between SST and orally administered azelastine. Figure 3 shows the profile of plasma azelastine concentration after oral administration, and these pharmacokinetic parameters assessed by a non-compartment model are shown in Tables 2 and 3 . When SST was administered at the dose double of human daily dosage (0.1 g/kg, twice a day), there were no significant differences between control and SSTtreated group. However, overdosage of SST (1 g/kg, twice a day) significantly reduced C max and increased MRT of azelastine (pϽ0.05, respectively). Since there was not statistically significant difference of AUC between control and SSTtreated group, SST might delay the absorption of azelastine without affecting the extent of bioavailability. Ohnishi et al. reported that oral administration of SST into rat significantly delayed the absorption of co-administered carbamazepine, and suggested that SST is likely to decrease gastric empty rate. 8) Their suggestion is reasonable, since a major active constituent of SST is ephedrine, which is a stimulant for sympathetic nerve and decreases gastric transit. 16, 17) The next experiment was conducted to evaluate the influences of ephedrine contained in SST. Since SST used in the present study contained 0.37 (w/w)% of ephedrine, the dosage of ephedrine hydrochloride was determined at 4.5 mg/kg, twice a day (corresponded to 1 g/kg of SST). SST, ephedrine hydrochloride or the vehicle was orally administered 4 times, and azelastine (10 mg/kg) was orally treated 1 h after the final administration of SST or ephedrine. The plasma concentrations of azelastine 2 h after oral azelastinetreatment were 406Ϯ63 ng/ml (vehicle-treated group, nϭ7), 334Ϯ50 ng/ml (ephedrine-treated group, nϭ7) and 197Ϯ58 (SST-treated group, nϭ6, pϽ0.05 vs. vehicle-treated group). This dosage of ephedrine slightly suppressed the plasma concentration of azelastine 2 h after oral administration; however, it was not corresponded to the suppressive effect of SST. It is suggested that other constituents than ephedrine in SST would make the absorption of azelastine hydrochloride delay. Possible interactive mechanism between SST and azelastine hydrochloride would be the formation of insoluble complexes during absorption phase. Noguchi et al. reported that some types of alkaloids form unsoluble salt with glycyrrhizin contained in Glycyrrhizae Radix in herbal decoction. 18) In clinical study, Glycyrrhizae Radix forms unsoluble complexes with tetracycline group of antibiotics to reduce their oral absorption. 19) Therefore, azelastine might form unsoluble salts with other compounds containing in SST in gastorintestinal tract, and became difficult to be absorbed through the gastric tract. In addition, it is possible that other kampo formulae which contain Glycyrrhizae Radix might inhibit the oral absorption of azelastine. However, the dosage of SST in the present study was much larger than that in the clinical case. In the animal pharmacological experiments, 20-times amount of human dosage is usual, since experimental animals have higher activity for metabolizing the drugs than human being in general, and since higher dosage exhibits the sharp pharmacological effects. The animal experiments in the present study had been schemed according to this practice of the dosage, but this might not be suitable for the pharmacokinetic experiments. At the double of human daily dose, SST did not made the absorption of azelastine delay. The possibility that SST reduce the absorption of azelastine hydrochloride could not be denied completely, however, it is suggested that SST would not cause pharmacokinetic interaction with azelastine hydrochloride clinically.
With worldwide expansion of the usage of herbal medicines, the problems of drug-herb interaction become popular in clinical pharmacology. 4, 20) Many reports about herb-drug interactions mentioning the inhibition or the promotion of metabolic enzymes have been published. For example, grapefruit juice and St. John's wort have been reported to strongly inhibit and promote the activity of CYP3A4, respectively. 21, 22) However, there are few reports about the formation of insoluble complexes between herbal and modern medicines during absorption phase. To prevent adverse effects or disadvantage dependent on the interactions between herbal and modern medicines, wide and detailed investigations of the interactions are required.
In conclusion, oral administration of SST at overdosage might reduce the absorption of azelastine hydrochloride. However, unless it is used at usual dosage, SST would not cause pharmacokinetic interaction with azelastine hydrochloride clinically.
